Latest Italy News

Boresight Ltd (ASX: BST) recorded a 46% increase in revenue to $6.38 million for FY26, driven by global sales expansion and strategic investments including an $8 million IPO. Despite this growth, the company posted a $6.66 million net loss, largely due to increased operational expenses and significant share-based payments.

Prescient Therapeutics (ASX:PTX) has opened a $7 million Share Purchase Plan at a significant discount to advance its lead cancer therapy PTX-100 beyond a pivotal Dose Optimisation Committee review in late 2026.

International Graphite is advancing Australia’s first commercial graphite micronising plant at Collie, targeting commissioning by mid-2027. The facility promises a diverse range of superfine graphite products and potential annual EBITDA up to AUD 14.2 million based on current market conditions.

Rubicon Water's FY26 results reveal an 11.6% revenue drop to $61.1 million and a net loss widening to $15.7 million, impacted by US federal funding delays and currency headwinds. Despite this, the company secured $28.4 million in second-half contracts and holds a $47 million major project pipeline, underpinning confidence for FY27 growth.

Prescient Therapeutics cut its net loss by 4.4% to $7 million in FY26 while expanding its PTX-100 Phase 2a trial across three continents and securing key regulatory designations in Europe and the US.

International Graphite Limited has closed a $4.4 million placement, securing cornerstone investors including Xcelsior Capital to fund expansion of graphite processing operations in Australia and Europe.

ADX Energy has lodged applications for two offshore gas exploration permits adjacent to its existing Sicily Channel licence, aiming to extend its footprint in a geologically promising biogenic gas play.

Marquee Resources shareholders rejected key share issues tied to the Tungsten Mountain acquisition, prompting the company to scrap the deal and refocus capital on advancing and monetising its existing portfolio.

Vection Technologies has locked in $1.2 million in non-repayable government funding to advance four distinct R&D projects spanning AI, Extended Reality, digital health, and inclusive technology.

Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.

Fluence Corporation delivered a 14.7% revenue increase in H1 2026, driven by a 34.7% rise in higher-margin Smart Product Solutions and Recurring Revenue, alongside record backlog growth and strategic leadership appointments.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.